Publication:
LBA10 Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC): FORTITUDE-101 phase III study results

dc.contributor.authorS.Y. Rha
dc.contributor.authorR.A. Pazo Cid
dc.contributor.authorA. Fernandez Montes
dc.contributor.authorS. Qin
dc.contributor.authorS.J. Klempner
dc.contributor.authorA. Elme
dc.contributor.authorH.M. Türk
dc.contributor.authorC. Pozzo
dc.contributor.authorA. Ranceva
dc.contributor.authorJ. Li
dc.contributor.authorH. Yoon
dc.contributor.authorZ.A.A. Wainberg
dc.contributor.authorA. Zahlten-Kuemeli
dc.contributor.authorP. Yen
dc.contributor.authorS. Kaur
dc.contributor.authorK. Muro
dc.contributor.authorE.C. Smyth
dc.contributor.institutionauthorTÜRK, HACI MEHMET
dc.date.accessioned2026-10-25T13:40:12Z
dc.date.issued2025-09-01
dc.identifier.doi10.1016/j.annonc.2025.09.092
dc.identifier.issn0923-7534
dc.identifier.startpageS1620
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2025.09.092
dc.identifier.urihttps://hdl.handle.net/20.500.12645/42753
dc.identifier.volume36
dc.language.isoen
dc.publisherElsevier BV
dc.relation.ispartofAnnals of Oncology
dc.rightsopenAccess
dc.sourceOpenAire
dc.titleLBA10 Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC): FORTITUDE-101 phase III study resultsen
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication1b3a1540-7e57-405d-8a9d-f926d17dcc29
relation.isAuthorOfPublication.latestForDiscovery1b3a1540-7e57-405d-8a9d-f926d17dcc29

Files